Composition for preventing or treating diabetes mellitus comprising insulin and glp-1 agonist dual \/ glucagon, and a method for preventing or treating diabetes mellitus.More specifically, the present composition can inhibit the increase of body weight and reduce the risk of hypoglycaemia due to insulin Administration.Reducing the dose of Administration and significantly increase the compliance with the Drugs through a combined Administration of a long-acting insulin conjugate and a conjugate dual agonist of the glp-1 \/ long-acting glucagon.In addition, the Conjugate of long-acting insulin and the conjugate dual agonist of the glp-1 \/ long-acting glucagon in accordance with this can improve the sustainability and stability in vivo due to a dual agonist of insulin and glp-1 \/ glucagon binds to the region N of immunoglobulin FC peptidilo not through a Linker.Claim 1: a Pharmaceutical composition comprising insulin to treat diabetes mellitus and a dual agonist for glp-1 \/ glucagon.Claim 2: the composition according to claim 1, wherein the native insulin is insulin, Rapid acting insulin, the basal insulin, an insulin Analogue that is a variant of insulin prepared by any method of Substitution, addition, deletion, modification, Or their combinations of the amino acid sequence of the native insulin, or a fragment thereof,And the Dual agonist for glp-1 receptor \/ glucagon simultaneously Active glp-1 and glucagon receptors. Claim 3: the composition according to claim 1, wherein the Dual agonist of insulin and glp-1 \/ glucagon are prolonged Action.Claim 5: Composition according to claim 3, wherein each of the Dual agonist of insulin and glp-1 \/ long-acting glucagon is a Conjugate of a biocompatible material which is capable of extending the duration of activation is linked to insulin or Agoni This dual glp-1 \/ glucagon using a roller or a Covalent Bond.Claim 6: Composition according to claim 5, wherein the biocompatible material selected from the group consisting of
